Guillaume Daniellot - Straumann Holding President
| SAUHF Stock | USD 126.09 1.37 1.10% |
President
Mr. Guillaume Daniellot was Member of the Executive Management Board and Head Sales North America of Straumann Holding Ltd since January 1, 2016. Prior to that, he was Member of the Executive Management Board and Head Sales Western Europe at the Company from 2013. Having obtained a Bachelors degree in Physics from the University of Dijon and a Masters in Marketing from FGE in Tours, he completed his studies with a Masters in Business Administration at the ESC European School of Management in Paris. His professional career began in hospital product management initially at Coloplast and then at B. Braun, as an international business unit manager. He switched to the dental industry in 2001, joining Dentsply France, where he became Sales Marketing Director since 2016.
| Age | 53 |
| Tenure | 8 years |
| Phone | 41 61 965 11 11 |
| Web | https://www.straumann.com |
Straumann Holding Management Efficiency
The company has return on total asset (ROA) of 0.1222 % which means that it generated a profit of $0.1222 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3141 %, meaning that it generated $0.3141 on every $100 dollars invested by stockholders. Straumann Holding's management efficiency ratios could be used to measure how well Straumann Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Andy Polywacz | West Pharmaceutical Services | N/A | |
| Roger Graham | Teleflex Incorporated | N/A | |
| Patrik Eriksson | Envista Holdings Corp | 56 | |
| Quintin Lai | West Pharmaceutical Services | 53 | |
| Brian Andrews | The Cooper Companies, | 45 | |
| SueJean Lin | Alcon AG | 65 | |
| Robert Douglas | ResMed Inc | 64 | |
| James Ferguson | Teleflex Incorporated | N/A | |
| Silji Abraham | West Pharmaceutical Services | 52 | |
| Aileen RuffPatry | West Pharmaceutical Services | N/A | |
| Alain Morvan | Coloplast A | N/A | |
| Thomas Spoerel | Becton Dickinson and | 45 | |
| Jeffrey Kappler | Envista Holdings Corp | 41 | |
| Anders LonningSkovgaard | Coloplast A | 51 | |
| Howard Yu | Envista Holdings Corp | 51 | |
| Daniel Woolson | ICU Medical | 47 | |
| Jim Hollingshead | ResMed Inc | 57 | |
| Alexandre Conroy | Becton Dickinson and | 57 | |
| George Miller | West Pharmaceutical Services | 64 | |
| Annette Favorite | West Pharmaceutical Services | 59 | |
| Christopher Ryan | West Pharmaceutical Services | 63 | |
Management Performance
| Return On Equity | 0.31 | |||
| Return On Asset | 0.12 |
Straumann Holding Leadership Team
Elected by the shareholders, the Straumann Holding's board of directors comprises two types of representatives: Straumann Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Straumann. The board's role is to monitor Straumann Holding's management team and ensure that shareholders' interests are well served. Straumann Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Straumann Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Holger Haderer, Head Board | ||
| KokKien Loh, Head Board | ||
| Wolfgang Becker, Head of Sales for Central Europe and Member of Executive Management Board | ||
| Aurelio Sahagun, Head Board | ||
| Matthias Schupp, Member of the Executive Management Board, Head Sales Latin America, CEO of Neodent | ||
| Camila Finzi, Head Management | ||
| Peter Hackel, CFO Board | ||
| Alastair Robertson, Head Board | ||
| Rahma Samow, Head Board | ||
| Guillaume Daniellot, Executive Vice President Sales Western Europe, Member of the Management Board |
Straumann Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Straumann Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 17.87 B | |||
| Shares Outstanding | 158.89 M | |||
| Shares Owned By Insiders | 33.39 % | |||
| Shares Owned By Institutions | 35.71 % | |||
| Price To Earning | 18.51 X | |||
| Price To Book | 9.87 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Straumann Pink Sheet
Straumann Holding financial ratios help investors to determine whether Straumann Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Straumann with respect to the benefits of owning Straumann Holding security.